A research group led by Prof. PIAO Hailong from the Dalian Institute of Chemical Physics (DICP) of the Chinese Academy of Sciences (CAS) and their collaborators have characterised the cellular composition and spatial architecture of tumour microenvironment in human multiple primary lung cancers (MPLCs) by integrating single-cell RNA-seq and spatial transcriptomics.
This study was published in Cell Death & Disease.
MPLCs refer to several primary tumours growing synchronously in the lung. With the widespread of high-resolution computed tomography, MPLCs are being diagnosed more frequently. However, it is still difficult to distinguish MPLC and intrapulmonary metastasis (IPM) in clinic, especially in cases of similar histologies.
In this study, the researchers conducted an integrative analysis of both single-cell transcriptome and spatial transcriptome data based on bioinformatics and machine learning methods.
They identified a previously undescribed sub-population of epithelial cells termed as CLDN2+ alveolar type II (AT2), specifically enriched in MPLCs. Possessing a relatively stationary state, this subtype played an important role in cellular communication, aggregating spatially in tumour tissues and dominating the malignant histopathological patterns.
The researchers verified that the CLDN2 protein expression could help distinguish MPLCs from intrapulmonary metastasis and solitary lung cancer.
In addition, they found a cell surface receptor TNFRSF18/GITR highly expressed in T cells of MPLCs, which suggested that TNFRSF18 was one potential immunotherapeutic target in MPLCs.
Source: Dalian Institute of Chemical Physics, Chinese Academy Sciences
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.